Skip to Main Content

Author Details

Mark J Ratain
University of Chicago
1985
571
79
PMIDPaper TitleJournal TitlePublished Year
38048579An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.Ann Intern Med2024
38062849Special designations and the US Food and Drug Administration's "dual mandate".J Natl Cancer Inst2024
36729768Implementation of pharmacogenomics into inpatient general medicine.Pharmacogenet Genomics2023
37806256Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?Eur J Cancer2023
37950004Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?Nat Biotechnol2023
37651126Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?JAMA Oncol2023
37542109Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.Br J Cancer2023
37450776Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.JCO Oncol Pract2023
37230253Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.Ann Oncol2023
36624662In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.J Clin Pharmacol2023
36780590US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?J Clin Oncol2023
34570085Anesthesia providers as stakeholders to adoption of pharmacogenomic information in perioperative care.Pharmacogenet Genomics2022
35383711Two polymorphic gene loci associated with treprostinil dose in pulmonary arterial hypertension.Pharmacogenet Genomics2022
35834770Oncology Drug Prescribing: The Influences of Greed and Fear.JCO Oncol Pract2022
35467243Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.Invest New Drugs2022
35395499Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.Value Health Reg Issues2022
35394660Lorlatinib Exposed: A Far From Optimal Dose.Clin Pharmacol Ther2022
35362793Lurbinectedin-induced thrombocytopenia: the role of body surface area.Cancer Chemother Pharmacol2022
35816636The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.Blood Adv2022
35412678Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.J Clin Pharmacol2022
36047275An Expanded Role for IRBs in the Oversight of Research Biopsies.Ethics Hum Res2022
35288585Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.NPJ Breast Cancer2022
34951144Subcutaneous Atezolizumab: A Jab Without a Benefit.Clin Pharmacol Drug Dev2022
34854077Dose Optimization of Pembrolizumab: Less May Be More.Clin Pharmacol Ther2022
34853435Correction: Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J Cancer2022
35213469Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.Anesth Analg2022
35090043Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.Cancer2022
34648187Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.J Clin Pharmacol2022
34616010Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients.Br J Cancer2022
34528705Genome-wide association studies of survival in 1520 cancer patients treated with bevacizumab-containing regimens.Int J Cancer2022
32958699Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).Clin Cancer Res2021
33818816Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib.Br J Clin Pharmacol2021
33506753Impact and applicability of pharmacogenomics in rheumatology: an integrated analysis.Clin Exp Rheumatol2021
33555940Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.J Clin Oncol2021
33662094The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check.JAMA Oncol2021
34880460Combination therapy patents: a new front in evergreening.Nat Biotechnol2021
34994622Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist.JCO Precis Oncol2021
34376839Negative innovation: when patents are bad for patients.Nat Biotechnol2021
34376788Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.Pharmacogenomics J2021
34725343Underrepresented patient views and perceptions of personalized medication treatment through pharmacogenomics.NPJ Genom Med2021
34543056Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?J Clin Oncol2021
34458686Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system.JAMIA Open2021
34423496Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.Oncologist2021
34149004Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance).Pharmacogenet Genomics2021
34010057The Right Dose: From Phase I to Clinical Practice.Am Soc Clin Oncol Educ Book2021
34263311Validation of a Large Custom-Designed Pharmacogenomics Panel on an Array Genotyping Platform.J Appl Lab Med2021
34168049Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.Clin Cancer Res2021
33210302COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.Clin Pharmacol Ther2021
33237281Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.JAMA Oncol2021
33147355Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab.Clin Pharmacol Ther2021
  • 1 - 50 of 571

Recommended Authors

Gideon M Blumenthal
Oncology Center of Excellence
Career Start Year 2008
Number of shared co-authors 6
Julia A Beaver
Center for Drug Evaluation and Research
Career Start Year 2007
Number of shared co-authors 6
Kari M Morrissey
Amunix Pharmaceuticals
Career Start Year 2006
Number of shared co-authors 9
Jordi Rodon
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 10
Shuiying Hu
The Ohio State University
Career Start Year 2005
Number of shared co-authors 7
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 5
Neeltje Steeghs
Netherlands Cancer Institute-Antoni Van Leeuwenhoek
Career Start Year 2003
Number of shared co-authors 4
Kristine R Crews
St. Jude Children's Research Hospital
Career Start Year 2001
Number of shared co-authors 36
Cristina Rodr??guez-Antona
Spanish National Cancer Research Center (CNIO)
Career Start Year 2000
Number of shared co-authors 9
Pingfu Fu
Case Western Reserve University
Career Start Year 2000
Number of shared co-authors 8
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 3
Elisabeth I Heath
Karmanos Cancer Center, Wayne State University
Career Start Year 1999
Number of shared co-authors 8
Salvador Fudio
Clinical Development
Career Start Year 1998
Number of shared co-authors 1
Elizabeth Garrett-Mayer
Center for Research and Analytics, American Society of Clinical Oncology
Career Start Year 1997
Number of shared co-authors 14
Primo N Lara
University of California Davis Comprehensive Cancer Center
Career Start Year 1996
Number of shared co-authors 12
Wells A Messersmith
University of Colorado Anschutz Medical Campus
Career Start Year 1995
Number of shared co-authors 8
Sharyn D Baker
Ohio State University
Career Start Year 1994
Number of shared co-authors 20
Stefan Sleijfer
Erasmus MC Cancer Institute, University Medical Center Rotterdam
Career Start Year 1994
Number of shared co-authors 5
Alex Sparreboom
Ohio State University
Career Start Year 1994
Number of shared co-authors 16
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Career Start Year 1993
Number of shared co-authors 4
Cynthia Sung
Health Services and Systems Research, Duke-NUS Medical School
Career Start Year 1990
Number of shared co-authors 2
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 11
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 7
Chris Twelves
Leeds Teaching Hospitals NHS Trust, University of Leeds
Career Start Year 1986
Number of shared co-authors 6
David C Smith
Rogel Comprehensive Cancer Center, University of Michigan ann arbor
Career Start Year 1985
Number of shared co-authors 11
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 6
Giuseppe Giaccone
Meyer Cancer Center
Career Start Year 1981
Number of shared co-authors 14
Anne Monks
Institute of Biomedical Engineering (IBME), University of Oxford
Career Start Year 1976
Number of shared co-authors 1
Richard Simon
National Cancer Institute
Career Start Year 1975
Number of shared co-authors 5
Ronald de Wit
Erasmus MC Cancer Institute
Career Start Year 1972
Number of shared co-authors 5

Collaborators

Howard L McLeod
Center for Precision Medicine and Functional Genomics, Utah Tech University
Co-authored papers 28
Mary Eileen Dolan
University of Chicago
Co-authored papers 24
Kouros Owzar
Duke University
Co-authored papers 24
Nancy J Cox
Vanderbilt University Medical Center
Co-authored papers 20
Michiaki Kubo
Co-authored papers 20
Deanna L Kroetz
University of California San Francisco
Co-authored papers 16
Mary V Relling
Departments of Pharmaceutical Sciences.
Co-authored papers 13
Ezra E W Cohen
university of california san diego Health System
Co-authored papers 12
David O Meltzer
The University of Chicago
Co-authored papers 12
Russ B Altman
Stanford University
Co-authored papers 11
Edwin H Cook
Co-authored papers 10
Richard M Weinshilboum
Mayo Clinic
Co-authored papers 10
Teri E Klein
Stanford University
Co-authored papers 9
Yusuke Nakamura
Japanese Foundation for Cancer Research
Co-authored papers 9
Kathleen M Giacomini
University of California San Francisco
Co-authored papers 8
Rita Nanda
Co-authored papers 8
Eric R Gamazon
Vanderbilt University Medical Center
Co-authored papers 8
Julie A Johnson
Department of Pharmacotherapy and Translational Research, University of Florida
Co-authored papers 7
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Fay J Hlubocky
Maclean Center for Clinical Medical Ethics, University of Chicago Medicine
Co-authored papers 5
Scott T Weiss
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 5
Eric P Winer
Dana-Farber Cancer Institute
Co-authored papers 5
Clifford A Hudis
Memorial Sloan Kettering Cancer Center, USA American Society of Clinical Oncology
Co-authored papers 5
Dan M Roden
Vanderbilt University Medical Center
Co-authored papers 5
Alan R Shuldiner
University of Maryland School of Medicine
Co-authored papers 5
Eric J Small
University of California san francisco
Co-authored papers 5
Donald A Berry
MD Anderson Cancer Center
Co-authored papers 4
Samuel L Volchenboum
University of Chicago
Co-authored papers 4
Jeffrey Peppercorn
Massachusetts General Hospital, Harvard Medical School
Co-authored papers 4
Heather E Wheeler
Co-authored papers 4
Release 1.2